
HTGF backs seed round for Adivo
German early-stage investor High-Tech Gründerfonds (HTGF) has backed a seed funding round for pet therapeutics company Adivo.
Corporate investors Occident Group and MorphoSys have also taken part in the round.
The Munich-headquartered business plans to accelerate therapeutic antibody programs as well as seeking collaborations with pharmaceutical partners.
HTGF invested from its third venture fund, which closed on €316.5m in May this year. It generally makes initial investments of €1-3m.
Company
Adivo was founded by medical doctor Kathrin Ladetzki-Baehs in 2018 and is headquartered in Martinsried near Munich. The company specialises in developing species-specific therapeutic antibodies for pets.
People
Adivo – Kathrin Ladetzki-Baehs (managing director).
High-Tech Gründerfonds – Lena Krzyzak (investment manager).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater